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Summary
Epidemiological data are essential for monitoring trends 
and outbreaks of infectious diseases in the general pop-
ulation. The reporting system pursuant to the Infection 
Protection Act in Germany results in a very good quality 
of timely nationwide data on all reportable diseases in-
cluding those relevant for the blood supply: HIV, hepati-
tis C, hepatitis B and syphilis. Notifications of acute hep-
atitis B and first-time diagnosed hepatitis C infections in 
the general population showed a declining trend in the 
past years, but the number of reports of HIV and syphilis 
infections increased until 2007 especially among men 
who have sex with men. New preventive strategies 
should also address changes in sexual behavior. The 
specific surveillance of blood donors is an important part 
of the hemovigilance system. The highly effective donor 
selection process results in a small number of confirmed 
infections among donors in Germany. The surveillance 
data enable us to identify specific trends that might chal-
lenge blood safety like the increase in HIV infections 
among repeat donors. Specific evaluations are per-
formed when needed. These additional studies can be 
used to modify guidelines or recommendations and to 
(re)evaluate the need for or the effect of further testing. 
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Zusammenfassung
Infektionsepidemiologische Daten sind wichtig, um Ent-
wicklungen der Infektionsprävalenz und -inzidenz und 
Häufungen zu identifizieren. Die Überwachung von Infek-
tionskrankheiten gemäß Infektionsschutzgesetz erlaubt 
in Deutschland eine zeitnahe nationale Erfassung wichti-
ger Infektionsdaten der Bevölkerung einschließlich sol-
cher Infektionen, die für die Blutsicherheit von Relevanz 
sind wie HIV, Hepatitis C, Hepatitis B und Syphilis. Die 
Meldungen von akuten Hepatitis-B- und erstmals diag-
nostizierten Hepatitis-C-Infektionen in der Allgemein-
bevölkerung zeigten in den letzten Jahren einen rückläu-
figen Trend. Die Anzahl von gemeldeten HIV- und Syphi-
lis-Infektionen hingegen stieg bis zum Jahr 2007 an, vor 
allem unter Männern, die Sex mit Männern haben. Prä-
ventionsmaßnahmen sollen künftig auch das veränderte 
Sexualverhalten von einigen Hauptbetroffenengruppen 
berücksichtigen. Die spezifische Überwachung von Blut-
spendern stellt einen wichtigen Teil des Hämovigilanz-
systems dar. Die hocheffektive Spenderauswahl führt 
dazu, dass nur wenige bestätigte Infektionen unter Spen-
dern in Deutschland diagnostiziert werden. Diese infekti-
onsepidemiologischen Daten dienen dazu, Entwicklun-
gen zu erkennen, die für die Blutsicherheit von Bedeu-
tung sein könnten wie der Anstieg von HIV-Infektionen 
unter Mehrfachspendern. Ergänzende epidemiologische 
Studien werden bei Bedarf durchgeführt. Diese Daten 
können dazu dienen, Empfehlungen oder Richtlinien zu 
modifizieren und die Notwendigkeit von Screening-Tests 
zu prüfen. 
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present, i.e., those notified already in the past. In order to 
 facilitate this, the reports are limited to first-time diagnosed 
HCV infections, regardless whether acute or chronic hepatitis 
C infection is present. In contrast, hepatitis B notifications en-
compass acute hepatitis B only. The notifications of HBV and 
HCV infections have to be made to the local health authority 
within 24 h after diagnosis so that precautionary measures to 
prevent further spread of the infection can be initiated. The 
notifications include demographical data, address of the treat-
ing medical facility, previous exposures as a proxy for likely 
transmission mode and the information whether the patient 
has donated blood, plasma or organs within the past 6 months. 
The reports fulfilling the reference definition are then ano-
nymized and forwarded within 14 days via federal state level 
health authority to the RKI using electronic data transfer. 
This enables the RKI to analyze trends and to detect out-
breaks. In case of an outbreak the RKI can offer assistance to 
the local health authorities. 
Pursuant to article 7 of the Infection Protection Act, any 
direct or indirect evidence of Treponema pallidum or HIV 
shall be notified on a non-named-patient basis by the labora-
tory. These notifications are sent by the diagnosing laboratory 
directly to the RKI within 14 days. They include demograph-
ical data, laboratory results, month and year of the diagnosis 
and information on the most likely mode of transmission pro-
vided by the treating physician (allowing the identification of 
true cases according to the reference definition). In case of 
HIV notifications, the HIV reports are additionally coded 
with an alphanumeric identifier (so-called ‘RKI-code’ i.e. se-
lected letters of the patients’ first and family names) to iden-
tify double notifications. If ‘transfusion’ or ‘treatment with 
blood products’ is reported as the most likely mode of trans-
mission, the case is followed up further, if possible, and the 
physician in charge is asked to report this severe adverse 
event to the responsible authority, the Paul-Ehrlich-Institute, 
so that look-back procedures can be initiated.
HIV/AIDS in the General Population
HIV started to spread in Germany in the late 1970s. The prev-
alence of HIV rose quickly in groups with a high risk of ac-
quiring an HIV infection, namely among men having sex with 
men (MSM), i.v. drug users and, in the early 1980s, patients 
receiving blood or blood products. Mandatory testing of 
blood donations, effective viral removal steps in the produc-
tion of plasma derivatives, preventive measures and changes 
in sexual behavior led to a decline in newly diagnosed infec-
tions in the respective groups. In the 1990s the number of 
newly diagnosed infections remained at a stable level of ap-
proximately 2,000/year but between 2000 and 2006 this 
number rose to a new level of 3,000 newly diagnosed infec-
tions/year [8]. The newly acquired infections occur mainly 
among MSM. In 2008 a total of 2,806 newly diagnosed HIV 
infections were reported to the RKI. For 85% of these infec-
tions the most likely mode of transmission was specified: 65% 
Introduction
The hemovigilance system is a set of surveillance procedures 
covering the whole transfusion chain (from the collection of 
blood and its components to the follow-up of recipients) and 
is intended to collect and assess information on unexpected or 
adverse effects resulting from the therapeutic use of blood 
products and to prevent their occurrence or recurrence. The 
collection of epidemiological data is an important part of this 
system providing information on the prevalence and incidence 
of transfusion relevant infections in the donor population. 
The reporting of adverse effects and epidemiological data is 
mandatory according to the EU directive on the EU level and 
pursuant to the Transfusion Act (Transfusionsgesetz) in Ger-
many [1– 3]. The data collected on a national level is reported 
to different international organizations like the World Health 
Organization (WHO), the Council of Europe and the Euro-
pean Centre for Disease Prevention and Control which facili-
tates international comparisons. Epidemiological data from 
blood donors have to be analyzed with care, especially since 
confirmed infections are rarely diagnosed in this highly se-
lected population. In Germany this task is performed by the 
Robert Koch Institute (RKI). In order to interpret data from 
blood donors, the epidemiological situation of the general 
population of the respective country must be known. In Ger-
many the nationwide mandatory reporting pursuant to the 
 Infection Protection Act (Infektionsschutzgesetz) includes 
HBV, HCV, HIV and syphilis infections [4].
General Infectious Disease Surveillance 
Surveillance systems for infectious diseases are the basis for 
effective public health measures in the prevention and control 
of infectious diseases. In 2001, the new German Infection Pro-
tection Act replaced aggregate with individual case reporting. 
The process was facilitated by the simultaneous introduction 
of electronic data transfer within the public health system [5]. 
On the international level EU Member States have had a 
number of obligations in the area of surveillance and control 
of communicable diseases since 1999 [6]. In 2005, at a global 
level, the WHO issued updated International Health Regu-
lations (IHR), which include broader obligations for notifica-
tion [7].
In Germany the main transfusion-relevant infections HIV, 
HCV, HBV and syphilis are reported on a mandatory basis 
pursuant to articles 6 and 7 of the Infection Protection Act. 
According to article 6 and 7, suspect cases, clinical cases of 
and deaths from patients with ‘acute infective hepatitis’ and 
laboratory diagnosis of HBV and HCV must be reported on a 
named-patient basis, if the evidence suggests an acute infec-
tion. Since it is not readily possible to discriminate between 
acute and chronic HCV infections, only those HCV infections 
shall not be reported where chronic infection is known to be 
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other, even European countries, Germany has a low HCV 
prevalence. Still it is estimated that 400,000–500,000 persons 
carry the virus in Germany. In 2008 6,195 first-time diagnosed 
HCV infections were reported to the health authorities, and 
the declining trend that was observed since 2004 continued 
[15]. HCV infections are more frequently diagnosed among 
male than female individuals. This difference is most pro-
nounced in the 25- to 29-year-olds. For 71.9% of all first-time 
diagnosed HCV infections in 2008 possible exposures to HCV 
were documented. Among these, i.v. drug use (36%), sexual 
exposure (31%) and invasive medical procedures (23%) were 
reported most often. Intravenous drug use is clearly associ-
ated with a risk of acquiring an HCV infection, and the fact 
that most i.v. drug users are men contributes greatly to the 
difference in HCV prevalence between men and women. Sur-
veillance of HCV infections among i.v. drug users still needs 
to be improved [16]. Heterosexual transmission of HCV is 
possible but not very effective, but there is increasing evi-
dence that HCV transmissions occur among MSM who en-
gage in high-risk activities [17]. This holds especially true for 
MSM who are co-infected with HIV. Further studies are on-
going to identify specific risk factors and to initiate preventive 
measures. The high proportion of individuals reporting medi-
cal procedures as a possible mode of transmission was due to 
interventions that dated back many years. The same was true 
for those 595 individuals who reported having received blood 
or blood products in the past. Nosocomial HCV infections 
occur only rarely but need special attention of the health au-
thorities. For instance outbreaks of HCV infections with com-
mon features like treatment in a specific medical practice can 
identify malpractice while handling infusions or syringes. 
HBV in the General Population
In the representative sample of 1998 of the German National 
Health Survey, the prevalence of antibodies against hepatitis 
B core antigen (HBc) was found to be 4.3% in East Germany 
and 7.7% in West Germany [14]. The prevalence of hepatitis 
B surface antigen was 0.6% (95% CI 0.4–0.8%). In 2008, 1,850 
notifications of acute HBV infections were made [15]. Of 
these only 822 (44%) fulfilled the criteria of the case defini-
tion while in the other 1,028 notifications the clinical signs of 
acute hepatitis B were not met or not reported. The number 
of reports of acute HBV infections declined in the past years 
most likely due to better data quality and increasing protec-
tion against HBV provided by vaccination in the general pub-
lic. Men are more often infected with HBV than women, es-
pecially men who are 25 years or older. For 83.6% of all re-
ported infections, exposures possibly leading to infection were 
reported. The most often reported exposure is sexual contact 
which is the most likely mode of transmission in Germany 
(43.2%). Medical procedures (8.3%), living in one household 
with a HBV-infected individual (6.0%) and i.v. drug use 
(4.1%) were reported less frequently. Occupational exposures 
leading to HBV infection are rare events, and numbers are 
of the patients were MSM, heterosexual contacts accounted 
for 17% of the newly diagnosed infections, 12% of the newly 
diagnosed cases came from high prevalence countries and 
were probably infected abroad, and 5% of the patients re-
ported i.v. drug use [9]. 
The increase of HIV infections among MSM between 2001 
and 2007 is most likely due to a combination of risk factors. 
Preventive strategies among MSM have changed, and the 
HIV status of a potential sex partner has become more impor-
tant for the decision if condoms are used or sexual practices 
are modified (so-called HIV serosorting). Additionally other 
sexually transmissible diseases (STDs), especially syphilis, 
have increased. STDs can on one hand increase the chances of 
becoming infected with HIV and on the other hand lead to an 
increased infectivity of individuals with HIV due to lesions of 
mucous membranes [10]. Heterosexual contacts leading to 
HIV infections were reported for 17% of patients. This pro-
portion has remained stable in the past 3 years. Two thirds of 
these HIV infections were most likely acquired in Germany. 
South East Asia was reported as region where the infection 
was acquired for 12% of men in this group, whereas Sub- 
Sahara Africa was reported for 5% of men and women in this 
group. For 5% of the women the region of infection was East-
ern Europe where HIV spreads mainly through i.v. drug use 
[11, 12]. Also the knowledge of different risk groups in the 
different regions of Europe and the world may lead to modifi-
cations of the donor selection process.
Syphilis in the General Population
In 2008 the RKI received 3,172 reports of syphilis infections 
fulfilling the reference definition. The total number of cases 
has remained stable since 2004, but there are shifting regional 
differences due to outbreaks [13]. Only 7% of all syphilis in-
fections occurred in women, but in regions with outbreaks es-
pecially among female sex workers the incidence might be 
significantly higher than average. In the region of Aachen for 
instance an increasing incidence of syphilis that can still be 
identified after 5 years was initially associated with an in-
crease of infections among female sex workers. The vast ma-
jority of syphilis infections occur among MSM, especially in 
urban areas like Berlin, Hamburg, Cologne and Frankfurt/M. 
Syphilis has reached a new endemic level in some subgroups 
of MSM with high numbers of sexual partners. The above 
mentioned HIV serosorting can also contribute to a further 
spread of syphilis infections if in case of HIV concordance 
condoms are not used. Public health measures should address 
the prevention of HIV, syphilis and other STDs in order to 
react to the changed sexual behavior among some subgroups 
of MSM.
HCV in the General Population
In the representative sample of 1998 of the German National 
Health Survey, the prevalence of antibodies against HCV was 
found to be 0.4% (95% CI 0.2–0.5%) [14]. Compared to 
128 Transfus Med Hemother 2010;37:125–130 Offergeld/Hamouda/Burger
Since needle sharing among i.v. drug users bears the highest 
risk of acquiring an HCV infection in Germany the donor se-
lection criteria are very effective in reducing the HCV preva-
lence in the donor population [25]. In addition, with better 
therapies at hand HCV infections might have been diagnosed 
more often by physicians in individuals with a possible expo-
sure in the past rather than diagnosing the infection ‘acciden-
tally’ while donating blood. 
The decrease in HBV infections among donors is most 
likely a result of ongoing efforts to provide protection by vac-
cination. Some blood establishments have implemented vac-
cination programs for donors which can add to transfusion 
safety. HBV vaccination may even be cost-effective compared 
to the implementation of additional nucleic acid amplification 
testing [26]. Still, most prevalent HBV infections in new and 
applicant donors are detected in the older age groups reflect-
ing the longer time period for exposure to the virus while inci-
dent infections among repeat donors occur mainly in the 35- 
to 54-year-old donors. This is consistent with occurrence of 
acute infections in the general population. Blood establish-
ment have to bear in mind that HBV is usually transmitted 
heterosexually in Germany, and special focus in the donor se-
lection process should be made on sexual contact with poten-
tially infected individuals. The surveillance data with respect 
to HBV infections were supplemented by a recommendation 
of the National Advisory Committee ‘Blood’. According to 
this recommendation the donors who tested positive for anti-
bodies against HBc shall be reported to the RKI. These addi-
tional reports will enable us to analyze the effect of the anti-
HBc testing [27, 28] on the overall blood safety and the donor 
pool after implementing the mandatory testing.
While the proportion of syphilis infections did not change 
in the past years, HIV infections among blood donors, espe-
cially repeat donors, showed an increasing trend from 2001 to 
2008. To check whether these changes among blood donors 
only reflect the increasing number of HIV infections in the 
general population or whether they are due to specific rea-
sons, additional investigations were carried out. A national 
matched case control study tested the hypothesis that HIV-
positive blood donors gave blood more often than HIV-nega-
tive donors in order to be tested for HIV (so-called HIV test 
seeking) and that the HIV test seekers also had relevant risks 
for acquiring an HIV infection. HIV test seeking is known to 
be a motivation for giving blood in a subgroup of donors [29, 
declining continuously. Vaccination has long been recom-
mended for all medical personnel and all other employees 
dealing with human material [18]. In addition to the vaccina-
tion of ‘risk groups’ the general vaccination of all children has 
been recommended since 1995. The percentage of children 
with complete vaccination against HBV increased continu-
ously since 1996, and in 2007 90.2% of all children entering 
school had completed the vaccination scheme [19]. This will 
eventually lead to a further decrease in HBV infections in 
Germany.
Surveillance among Blood Donors
Surveillance of the blood donor population is carried out at 
the RKI pursuant to article 22 of the Transfusion Act and in-
cludes HIV, HCV, HBV and syphilis infections [2]. Nation-
wide data are collected from all blood establishments in Ger-
many regardless of their respective organization. This enables 
data analysis on a national basis as well as on a regional level. 
A complementary guideline [20] and a recommendation of 
the National Advisory Committee ‘Blood’ [21] define the 
mode and extend of these reports: Quarterly and yearly re-
ports of the number of donors and donations stratified with 
respect to age group, sex, type of donation (whole blood, 
plasma, thrombocytes) and type of donor (first-time donor, 
repeat or regular donor) separately for each blood establish-
ment have to be reported. Also all confirmed positive HIV, 
HCV, HBV and syphilis infections among donors have to be 
reported. Additional information such as individual donation 
history, information on the presumed mode of transmission 
and detailed laboratory results are available from these 
donors.
In 2008 more than 550,000 samples of new and applicant 
blood and plasma donors were screened. Also more than 2.3 
million repeat donors were registered who gave more than 6.6 
million donations. The prevalence and incidence of the trans-
fusion-relevant infections per 100,000 donors are illustrated in 
table 1.
The prevalence and incidence of transfusion-relevant in-
fections among donors in Germany is very low. The preva-
lence of HCV and HBV infections among new and applicant 
donors and the HCV  and HBV seroconversions among re-
peat donors showed a decreasing trend since 2001 [22–24]. 
Table 1. Confirmed HIV, HCV, HBV and syphilis infections among blood donors in Germany in 2008
Type of donor and number of donors and donations HIV infections HCV infections HBV infections Syphilis infections
New donors (n = 569,990) 39 408 780 178
Prevalence/100,000 donors  6.8  71.5 136.7  31.2
Repeat donations/donors (n = 6,655,053/2,376,429) 61  53  34 105
Seroconversions/100,000 donations  0.9   0.8   0.5   1.6
Incidence/100,000 donors  2.6   2.2   1.4   4.4
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Within Europe an expert group coordinated and led by the 
European Directorate for Quality in Medicine and Health 
Care (EDQM) is currently investigating the situation and try-
ing to find a consensus on the impact of sexual risk behavior 
on blood safety. 
From our studies we conclude that one measure should be 
to address HIV test seeking directly in the donor selection 
process. This is only possible if alternative and free-of-charge 
HIV testing is available. In order to assure this, the RKI is 
continuously working with the local health authorities to 
maintain or even improve this offer in Germany. Nonetheless, 
the quality of DQs and the information material provided for 
donors is crucial for a good acceptance of the donor selection 
criteria. Therefore, efforts were made by a group of experts 
from the scientific society, the professional organization of 
physicians in transfusion medicine, and the National Advisory 
Committee ‘Blood’. The group developed a standardized and 
uniform DQ which focuses on simple, non-medical language, 
grouped questions, direct assessment of sexual risk behavior 
and tries to avoid lists (e.g. of diseases) as far as possible. The 
uniform DQ was tested on 6,500 new donors in four blood es-
tablishments of the German Red Cross and one University 
blood establishment who contributed greatly to the success of 
the study. Although it will never be possible to identify all 
previously unreported deferrable risks, the innovative method 
of testing a DQ on site will lead to results that can help to im-
prove the quality of the donor selection process. 
Conclusion
Epidemiological data of the blood donor population can add 
to transfusion safety because it facilitates analysis of risk fac-
30], but investigations in Norway found that HIV test seekers 
did not have particulars risks for acquiring an HIV infection 
[31]. In our study all HIV-positive donors between 2001 and 
2005 and matched controls were questioned anonymously 
about donor motivation, knowledge about donation and in-
fectious diseases and personal risk factors. This study revealed 
that HIV test seeking was significantly more frequent among 
the HIV-positive donors. The test seekers in this study admit-
ted (sexual) risk behavior significantly more often than do-
nors who did not quote this motivation for donation. The risk 
behavior reported most often was sexual contact between 
men even though according to the German guidelines MSM 
are permanently deferred from donating blood [25, 32]. Look-
ing at detailed epidemiological data from donors, these find-
ings are supported by the fact that a great proportion of HIV-
positive donors admit relevant risk behavior in the post-dona-
tion interview. In fact the proportion of MSM in the HIV-
posi tive donor population nearly reflects the proportion of 
MSM among newly infected HIV-positive individuals in the 
general population (fig. 1). 
There is obviously a number of donors who have unre-
ported deferrable risks, especially MSM, but also donors with 
heterosexual risk behavior. These donors might give false an-
swers in the donor questionnaire (DQ) and interview because 
(apart from the desire to receive a test result) they do not 
fully understand the questions or the need to give such infor-
mation. They might not accept the donor selection criteria be-
cause they consider them to be discriminatory, especially for 
MSM. The question whether the permanent deferral from 
blood donation for MSM should be changed to a temporary 
deferral leading to a better compliance with the deferral crite-
ria and eventually to higher safety of the blood supply has 
been discussed intensively on an international level [33–35]. 
Z:\Karger\Karger_Zeitschriften_2010\2010_transfusionsmedizin_tmh\81000703_TMH_3_10\03_texte\TMH_3_10_201004002_Offergeld_ZS.doc 10
Number of HIV+ donors








Fig. 1. HIV-positive 
donors (n = 221): 
Most likely mode of 
infection 2001–2008. 
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analyses. Additional studies like the one on HIV test seeking 
behavior or on the effect of screening for the presence of anti-
HBc can lead to concrete suggestions for the modification of 
donor selection criteria or recommendations for screening of 
blood donors even on an international level. The final evalua-
tion of the uniform donor questionnaire will also be of great 
interest in the near future.
tors and trends in the prevalence and incidence of relevant 
infectious diseases. Also changes in the prevalence and inci-
dence of transfusion-relevant infections in the general popula-
tion should be observed to interpret trends in the blood donor 
population correctly. The very good reporting system in Ger-
many for reportable diseases in the general population and 
the blood donor population represents a stable basis for such 
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